Sandbox:glomerular disease: Difference between revisions
Jump to navigation
Jump to search
Tarek Nafee (talk | contribs) Created page with "__NOTOC__ glomerular disease" |
No edit summary |
||
(3 intermediate revisions by 2 users not shown) | |||
Line 1: | Line 1: | ||
{| class="wikitable" | |||
! rowspan="2" |Glomerular Disease | |||
! colspan="3" |Physical Examination | |||
! colspan="8" |Laboratory Studies | |||
! colspan="2" |Management | |||
! rowspan="2" |Prognosis | |||
|- | |||
!Blood Pressure | |||
!Edema | |||
!Other Physical Manifestations | |||
!Proteinuria | |||
!Lipiduria | |||
!Albumin | |||
!Serum Lipids | |||
!C3/C4 | |||
!ANCA | |||
!Anti-GBM | |||
!Other Serologies | |||
!Initial Treatment | |||
!Maintenance Treatment | |||
|- | |||
|Diabetic Nephropathy | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |||
|Minimal Change Disease | |||
| | |||
| | |||
| | |||
| | |||
| +++ | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |||
|Primary FSGS | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |||
|Paraprotein Related Renal Disease | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |||
|Granulomatosis with polyangitis | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|✔ | |||
| | |||
| | |||
|PDN*;INN* | |||
|PDN*;AZA* | |||
| | |||
|- | |||
|Alport syndrome | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |||
|Goodpasture syndrome | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|✔ | |||
| | |||
|PDN*; INN*; PPH* | |||
| | |||
| | |||
|- | |||
|Eosinophilic granulomatosis with polyangiitis | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|✔ | |||
| | |||
|Eosinophilia; IgE | |||
|PDN* | |||
|Non severe: PDN*; MTX*, AZA*, HU* | |||
Severe: PDN*; INN*; AZA* or MTX* | |||
| | |||
|- | |||
|Microscopic polyangiitis | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|✔ | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|} | |||
<nowiki>*</nowiki> AZA=Azathioprine; HU=Hydroxyurea; INN=Cyclophosphamide; MTX=Methotrexate; PDN=Prednisone; PPH=Plasmapheresis | |||
__NOTOC__ | __NOTOC__ | ||
Latest revision as of 13:06, 16 November 2016
Glomerular Disease | Physical Examination | Laboratory Studies | Management | Prognosis | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Blood Pressure | Edema | Other Physical Manifestations | Proteinuria | Lipiduria | Albumin | Serum Lipids | C3/C4 | ANCA | Anti-GBM | Other Serologies | Initial Treatment | Maintenance Treatment | ||
Diabetic Nephropathy | ||||||||||||||
Minimal Change Disease | +++ | |||||||||||||
Primary FSGS | ||||||||||||||
Paraprotein Related Renal Disease | ||||||||||||||
Granulomatosis with polyangitis | ✔ | PDN*;INN* | PDN*;AZA* | |||||||||||
Alport syndrome | ||||||||||||||
Goodpasture syndrome | ✔ | PDN*; INN*; PPH* | ||||||||||||
Eosinophilic granulomatosis with polyangiitis | ✔ | Eosinophilia; IgE | PDN* | Non severe: PDN*; MTX*, AZA*, HU*
Severe: PDN*; INN*; AZA* or MTX* |
||||||||||
Microscopic polyangiitis | ✔ | |||||||||||||
* AZA=Azathioprine; HU=Hydroxyurea; INN=Cyclophosphamide; MTX=Methotrexate; PDN=Prednisone; PPH=Plasmapheresis